Adcock Shareholders Put Off Vote On CFR Acquisition To January
This article was originally published in PharmAsia News
Executive Summary
Adcock Ingram shareholders overwhelmingly agreed to delay a vote on a $1.24 billion acquisition offer from CFR Pharmaceuticals of Chile until January, delivering a blow to the major shareholder.